TO THE EDITOR

The N-methyl-D-aspartate (NMDA) receptor antagonist ketamine is one of the most attractive antidepressants for treatment-resistant major depression.[@B1],[@B2] I read the recent article by Murrough et al.[@B3] about the rapid and robust antidepressant effects of a single intravenous infusion of ketamine in treatment-resistant patients with major depression with great interest. In the two-site randomized controlled trial, they used the anesthetic benzodiazepine midazolam as a control drug to optimize their design and mitigate the effects of nonspecific factors on the antidepressant-related outcome. Analysis of the primary outcome measure showed that the ketamine group experienced greater improvement in terms of Montgomery-Åsberg depression rating scale (MADRS) scores than did the midazolam group. Furthermore, the response at 24 hours was also greater in the ketamine than in the midazolam group. Eight (17%) of the 47 patients receiving ketamine experienced significant dissociative symptoms immediately after the ketamine infusion, although these symptoms resolved by 2 hours post-infusion. The relationship between dissociative symptoms and the antidepressant effects of ketamine was not reported. Other common adverse events were observed in both groups. Because of dissociative side effects of ketamine, it is necessary to identify treatment-resistant patients who *should not* receive ketamine.[@B4]

Ketamine (or *RS* (±)-ketamine) is a racemic mixture containing equal parts of *R* (-)-ketamine and *S* (+)-ketamine. *S*-ketamine has an approximately fourfold greater affinity for NMDA receptors than does *R*-stereoisomer.[@B5] Furthermore, *S*-ketamine shows an approximately three-to-fourfold greater anesthetic potency and is associated with more undesirable psychotomimetic side effects compared with *R*-stereoisomer.[@B5] Recently, we reported that *R*-ketamine showed greater potency and longer-lasting antidepressant effects than did *S*-ketamine in a rodent model of depression.[@B6]

A positron emission tomography study in healthy volunteers demonstrated that psychotomimetic doses of *S*-ketamine markedly increased the cerebral metabolic rates of glucose (CMRglu).[@B7] In contrast, equimolar doses of *R*-ketamine tended to decrease CMRglu across the brain, producing no psychotic symptoms but, instead, a state of relaxation and well being.[@B7] Interestingly, at the doses tested, *R*-ketamine produced a state of relaxation and elation, which was correctly identified as a drug effect by all subjects, even though *R*-ketamine produced an only marginally significant change in mood scores.[@B7]

Taken together, these data suggest that the *R*-stereoisomer of ketamine would be an alternative antidepressant for ketamine as *R*-ketamine may be free of psychotomimetic side effects.
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